Core Viewpoint - The company, through its wholly-owned subsidiary Beihai Ruizhi, has entered into a partnership to establish a new investment fund focused on the healthcare industry, particularly innovative drugs and medical devices, with a total committed capital of 200 million yuan [1] Group 1: Investment Details - The partnership involves Beihai Ruizhi contributing 58 million yuan, representing 29% of the total committed capital [1] - The fund aims to invest primarily in innovative drugs, leveraging the expertise and capital advantages of professional investment institutions [1] Group 2: Strategic Implications - The investment is expected to enhance the company's capital operation capabilities and strengthen its competitiveness in the innovative drug sector [1] - The collaboration with professional investment institutions is anticipated to improve risk control and generate investment returns for the company [1]

Core Viewpoint - The company, Ruizhi Pharmaceutical, is establishing a partnership to invest in the healthcare industry, focusing on innovative drugs and medical devices, which is expected to enhance its capital operation capabilities and competitiveness [1] Investment Partnership - Ruizhi Pharmaceutical's wholly-owned subsidiary, Beihai Ruizhi Venture Capital Co., Ltd., signed a partnership agreement with Shenzhen Investment Control Donghai Investment Co., Ltd. and other limited partners to establish a new investment fund [1] - The total committed capital for the partnership is 200 million yuan, with Beihai Ruizhi contributing 58 million yuan, representing 29% of the total [1] Focus on Healthcare Sector - The newly formed partnership will primarily invest in the healthcare sector, with a strong emphasis on innovative drugs [1] - The collaboration with professional investment institutions is expected to leverage their investment capabilities, funding advantages, and risk control abilities to enhance the company's operations in the innovative drug industry [1]

Group 1 - The core point of the article is that Ruizhi Pharmaceutical (300149.SZ) has signed a partnership agreement to establish a new investment fund focused on the healthcare industry, particularly innovative drugs and medical devices [1] - The total committed capital for the partnership is RMB 200 million, with Beihai Ruizhi contributing RMB 58 million, representing 29% of the total [1] - The partnership involves collaboration with Shenzhen Investment Control Donghai Investment Co., Ltd. and other limited partners, indicating a strategic move to enhance investment capabilities in the healthcare sector [1] Group 2 - The newly established fund, tentatively named Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership (Limited Partnership), aims to invest primarily in innovative drugs [1] - The involvement of professional investment institutions suggests a structured approach to capital allocation in the healthcare market [1] - This initiative reflects a growing trend in the pharmaceutical industry towards investment in innovation and technology-driven healthcare solutions [1]

第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第六届董事会第十一次会 议于 2025 年 9 月 3 日以通讯方式召开。会议通知以书面、电话或电子邮件方 式送达。会议应到董事 6 人，实到 6 人。会议由公司董事长WOO SWEE LIAN 先生主持，公司高级管理人员列席了会议。本次会议召集与召开符合有关法律、 行政法规、部门规章和《公司章程》的有关规定。经与会董事认真审议，形成 决议如下： 1、审议通过了《关于全资子公司与专业投资机构共同投资的议案》 同意公司全资子公司北海睿智创业投资有限公司（以下简称"北海睿智"） 与专业投资机构深圳市投控东海投资有限公司及其他有限合伙人深圳市罗湖产 业促进合伙企业（有限合伙）共同出资设立深圳市罗湖东海睿智医药产业合伙 企业（有限合伙）（暂定名，具体以企业登记机关最终核准登记的名称为准）， 全体合伙人认缴出资总额为人民币20,000万元，其中北海睿智作为有限合伙人 以自有资金出资人民币5,800万元，占认缴出资总额的29%。 证券代码：300149 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-62 睿智医药科技股份有限公司 关于全资子公司与专业投资机构共同投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、与专业机构共同投资的概述 睿智医药科技股份有限公司（以下简称"公司"）全资子公司北海睿智创业 投资有限公司（以下简称"北海睿智"）与专业投资机构深圳市投控东海投资有 限公司（以下简称"投控东海"、"基金管理人"、"普通合伙人"、"执行事 务合伙人"）及其他有限合伙人深圳市罗湖产业促进合伙企业（有限合伙）签署 了《深圳市罗湖东海睿智医药产业合伙企业（有限合伙）合伙协议》，拟共同出 资设立深圳市罗湖东海睿智医药产业合伙企业（有限合伙）（暂定名，具体以企 业登记机关最终核准登记的名称为准，以下简称"合伙企业"或"基金"），全 体合伙人认缴出资总额为人民币 20,000 万元，其中北海睿智作为有限合伙人以 自有资金出资人民币 5,800 万元，占认缴出资总额的 29%。 本次投资事项已经公司第六届董事会第十一次会议审议通过，并授权公司管 理层办理本次投资相关事宜。本次投资事项在公 ...

一、进展情况 近日，上述全资子公司已完成工商登记及相关手续，并取得了广州市越秀区 市场监督管理局颁发的《营业执照》，相关登记信息如下： 名称：广东睿智医药投资有限公司 统一社会信用代码：91440104MAEUMUF74U 类型：有限责任公司（自然人投资或控股的法人独资） 证券代码：300149 证券简称：睿智医药 公告编号：2025-60 睿智医药科技股份有限公司 关于设立全资子公司进展暨完成工商登记的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 6 月 9 日召开了 第六届董事会第八次会议，审议通过了《关于设立股权投资全资子公司的议案》， 根据公司战略安排，同意公司使用自有资金 1,000 万元在广州设立全资子公司广 州睿盈股权投资有限公司（暂定名，具体以市场监督管理部门最终核准登记名称 为准）。具体内容详见公司于 2025 年 6 月 11 日在巨潮资讯网（www.cninfo.com.cn） 上披露的《关于投资设立全资子公司的公告》（公告编号：2025-50）。 注册地址：广州市越秀区东风 ...

Group 1: Company Performance - In the first half of 2025, the company achieved a revenue of 5.34 billion yuan, representing a year-on-year growth of 14.75% [3] - The net profit attributable to shareholders reached 25.38 million yuan, with a significant year-on-year increase of 140.35% [3] - The company's gross margin has improved significantly, indicating a fundamental enhancement in its financial health [3] Group 2: Strategic Planning - The company is focusing on a "one-stop service platform" for drug development, promoting a full-package service model to reduce communication costs and enhance efficiency [3] - The integration of AI technology into drug research and development is a key strategy, with successful applications in multiple core business areas [3] - The company aims to leverage its technological service capabilities to fill critical gaps in the industry chain and foster collaborative ecosystems [3] Group 3: Market Expansion - Over 80% of the company's revenue comes from overseas clients, with approximately 20% from the Asia-Pacific region [4] - The company is actively expanding its presence in the Asia-Pacific market and enhancing its service capabilities in Europe and the US [4] - New modality drug business has seen a significant increase, with orders from XDC and peptides rising from 8% to 17% year-on-year [5] Group 4: Customer Strategy - The company aims to secure long-term contracts with multinational corporations (MNCs) while also empowering more biotech firms as long-tail customers [5] - The customer structure is primarily composed of small to medium biotech firms, with a trend of MNC clients returning [5] - The company is focusing on enhancing collaboration with MNCs to stabilize its customer base and performance [5] Group 5: Financial Goals and Milestones - The long-term strategic goal is to capture 1% of the global CXO market, which is valued at 1 trillion USD [7] - The company targets a revenue increase to 2.5 billion yuan and a net profit of no less than 200 million yuan by 2027 [7] - Key milestones for the upcoming year include enhancing full-package services, establishing laboratories in Boston and the UK, and improving overall service capabilities [8]

人民财讯9月3日电，企查查APP显示，近日，广东睿智医药（300149）投资有限公司成立，注册资本 1000万元，经营范围包含：人工智能公共服务平台技术咨询服务；信息技术咨询服务；信息咨询服务 (不含许可类信息咨询服务)等。企查查股权穿透显示，该公司由睿智医药全资持股。 ...

Core Insights - The strategic cooperation between Ruizhi Pharmaceutical and Haiyou Biological was officially established on August 29, focusing on the development of small nucleic acid drugs and innovative delivery technologies [1] Company Summary - Ruizhi Pharmaceutical (300149) and Haiyou Biological will leverage their strengths in small nucleic acid drug research and innovative delivery technology [1] - The collaboration aims to enhance the development and upgrade of new delivery systems, specifically targeting extrahepatic delivery [1] Industry Summary - The partnership is positioned at the forefront of the industry, aiming to expand the application boundaries of small nucleic acid drugs [1] - The initiative is expected to bring more possibilities for the treatment of extrahepatic tissue diseases [1]

Core Insights - The company, Ruizhi Pharmaceutical, reported a significant increase in revenue and net profit for the first half of 2025, with total revenue reaching 534 million yuan, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, up 140.35% compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 534 million yuan, compared to 465 million yuan in the same period of 2024, reflecting a growth of 14.75% [1] - The net profit for the first half of 2025 was 25.38 million yuan, a significant turnaround from a loss of 62.91 million yuan in the previous year, marking a 140.35% increase [1] - The gross profit margin improved to 29.01%, up 77.98% year-on-year, while the net profit margin reached 4.75%, an increase of 135.07% [1] - The total of selling, administrative, and financial expenses was 108 million yuan, accounting for 20.19% of revenue, a decrease of 6.51% from the previous year [1] Operational Improvements - The company has implemented management system optimizations and established a more stable and efficient organizational structure, enhancing collaboration across departments [3] - A significant restructuring of the business development (BD) team has occurred, expanding the team size from over 10 to nearly 30, with a focus on international markets, particularly in the U.S. and Europe [3][4] - The strategic focus has shifted to a "full-package service" model, enhancing the company's ability to provide comprehensive research and development solutions, thereby improving operational efficiency and competitive advantage in the CRO market [4]